AbbVie Inc. $ABBV Shares Sold by LaFleur & Godfrey LLC

LaFleur & Godfrey LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 5.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 71,689 shares of the company’s stock after selling 3,873 shares during the quarter. AbbVie accounts for approximately 2.0% of LaFleur & Godfrey LLC’s investment portfolio, making the stock its 15th largest holding. LaFleur & Godfrey LLC’s holdings in AbbVie were worth $16,380,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Brighton Jones LLC lifted its stake in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. grew its stake in shares of AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after buying an additional 789 shares in the last quarter. Ieq Capital LLC raised its holdings in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after buying an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC raised its holdings in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after buying an additional 612,702 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Down 1.0%

Shares of NYSE ABBV opened at $206.12 on Wednesday. AbbVie Inc. has a fifty-two week low of $176.57 and a fifty-two week high of $244.81. The business has a 50 day moving average price of $214.17 and a two-hundred day moving average price of $221.34. The firm has a market cap of $364.46 billion, a PE ratio of 101.54, a price-to-earnings-growth ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.46 EPS. On average, analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. AbbVie’s payout ratio is presently 340.89%.

Insider Activity

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and raised guidance spurred a rally: AbbVie reported stronger‑than‑expected Q1 results and lifted 2026 guidance, which pushed the stock higher in early May as investors reassessed growth prospects from Skyrizi, Rinvoq and the pipeline. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Analyst and retail attention following the quarter: Coverage from Zacks highlights the company as a top‑searched/“trending” stock, reflecting elevated investor interest after the beat — attention that can amplify moves on earnings or guidance news. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Dividend appeal remains strong: Multiple income‑focused outlets continue to list AbbVie as a high‑yield dividend candidate, supporting demand from dividend investors despite valuation considerations. Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
• Neutral Sentiment: Positive clinical and real‑world data showcased at DDW: AbbVie presented long‑term and real‑world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in IBD, which supports the commercial outlook but will take time to materially change revenue trajectory. AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
• Neutral Sentiment: Industry tech/AI events mention AbbVie involvement: Participation in life‑science AI forums signals digital investment but is unlikely to move near‑term fundamentals. Zifo’s SiEE Boston Summit Charts New Roadmap for ‘Practical AI’ in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
• Negative Sentiment: Regulatory/manufacturing setback for a wrinkle treatment: The U.S. FDA declined to approve AbbVie’s wrinkle product over manufacturing concerns (reported April 23), a near‑term headwind that can pressure sentiment and highlight execution risk on noncore franchises. US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)

Analysts Set New Price Targets

ABBV has been the topic of several recent research reports. Barclays initiated coverage on AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Royal Bank Of Canada began coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target for the company in a report on Thursday, April 30th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $252.90.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.